- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06062342
Five Point Initiative: A Bundled Implementation Strategy to Address the HIV Epidemic in Black Communities (FPI)
July 28, 2025 updated by: Sannisha K Dale, University of Miami
Five Point Initiative: A Cluster Randomized Trial of a Bundled Implementation Strategy to Address the HIV Epidemic in Black Communities
The purpose of this study is to assess the effectiveness of the FPI bundled implementation strategy in increasing HIV testing, Pre-exposure prophylaxis (PrEP) linkage (e.g., prescription) and knowledge, and condom use/access.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
20400
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sannisha Dale, PhD
- Phone Number: (305) 243-6714
- Email: sdale@med.miami.edu
Study Contact Backup
- Name: SHINE Research Program
- Email: shineresearch@miami.edu
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- University of Miami
-
Contact:
- Sannisha Dale, PhD
- Phone Number: (305) 243-6714
- Email: sdale@med.miami.edu
-
Principal Investigator:
- Sannisha Dale, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Any individual present during the community events at the "five points" (barbershop, hair/beauty salon store or salon, corner store/grocery/neighborhood restaurant, laundromats, car service provider [e.g. gas station, mechanic, car wash]) in predominantly Black communities in Miami where HIV prevalence is high.
- Pre- and Post-assessment: Individuals are only eligible to complete the survey one time during the Pre-Intervention and during the Post-Intervention phases.
- Intervention: Individuals are only eligible to participate in the Intervention phase of this study once every 6 months.
Exclusion Criteria:
- Individuals who are unable to completely and fully understand the informed (verbal) consent process and the study procedures.
- Individuals who have previously completed the survey during the Pre-Intervention and Post-Intervention phases.
- Individuals who have participated in the Intervention phase of this study within less than 6 months.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: FPI Group
Participants in this group will receive the FPI intervention at any FPI coordinated outreach event (4-5 hours) during a 21 month period
|
The FPI intervention will be conducted twice per month (across 21 months) in a zip code, and each event will last approximately 4-5 hours.
At the event, participants will receive HIV testing, PrEP linkage (e.g., prescription) and knowledge, and condom and use/access.
|
|
No Intervention: Pre-intervention Assessment Group
We will conduct pre-assessment events (4-5 hours) during 1.5 months in each zip code (prior to the introduction of the FPI intervention) to capture information from residents /participants via survey.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in number of residents with recent HIV testing
Time Frame: Up to 23 months
|
Will be reported as proportion of residents with recent (within 12 months) HIV testing as measured by Five Point Initiative - Community Survey
|
Up to 23 months
|
|
Change in number of residents with PrEP prescription
Time Frame: Up to 23 months
|
Will be reported as proportion of residents with PrEP prescription as measured by Five Point Initiative - Community Survey
|
Up to 23 months
|
|
Change in PrEP knowledge as measured by Five Point Initiative - Community Survey
Time Frame: Baseline and up to 23 months
|
Will be reported as the proportion of residents that indicated 'Yes' on the survey.
|
Baseline and up to 23 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in condom use as measured by Five Point Initiative - Community Survey
Time Frame: Baseline and up to 23 months
|
Will be reported as the proportion of residents that indicated 'No' on the survey
|
Baseline and up to 23 months
|
|
Change in condom access as measured by Five Point Initiative - Community Survey
Time Frame: Baseline and up to 23 months
|
Will be reported as the proportion of residents that indicated 'Yes' on the survey
|
Baseline and up to 23 months
|
|
Proportion of residents with recent HIV testing by health organizations
Time Frame: Up to 23 months
|
Proportion of residents with recent (within 12 months) HIV testing by each of the participating health organizations.
|
Up to 23 months
|
|
Number of residents with PrEP prescription by health organizations
Time Frame: Up to 23 months
|
Number of residents with PrEP prescription by each of the participating health organizations.
|
Up to 23 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Sannisha Dale, PhD, University of Miami
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 2, 2024
Primary Completion (Estimated)
December 1, 2028
Study Completion (Estimated)
June 30, 2029
Study Registration Dates
First Submitted
September 25, 2023
First Submitted That Met QC Criteria
September 25, 2023
First Posted (Actual)
October 2, 2023
Study Record Updates
Last Update Posted (Actual)
July 29, 2025
Last Update Submitted That Met QC Criteria
July 28, 2025
Last Verified
July 1, 2025
More Information
Terms related to this study
Other Study ID Numbers
- 20230484
- 1R01MH134269-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hiv
-
Duke UniversityGilead SciencesRecruitingHIV Prevention | HIV Pre-exposure Prophylaxis | HIV Prevention Program | HIV Prevention and Care | HIV Pre-exposure Prophylaxis UseUnited States
-
Federal University of São PauloGilead SciencesCompleted
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
Institute of HIV Research and Innovation Foundation...National Institutes of Health (NIH)RecruitingHIV Prevention | PrEP Adherence | HIV Related StigmaThailand
-
University of Alabama at BirminghamNational Institute of Mental Health (NIMH)RecruitingPrEP | HIV | HIV Prevention | PrEP UptakeUnited States
-
ANRS, Emerging Infectious DiseasesNot yet recruitingAntiretroviral Therapy | HIV-1 Infection | HIV Reservoir
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH)RecruitingFeasibility | HIV Prevention | PrEP Uptake | Acceptability | HIV Self-testing | Male Partners of HIV-negative Postpartum WomenSouth Africa
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
Clinical Trials on FPI
-
AstraZenecaAstraZenecaRecruitingRenal Cell Carcinoma | Gastric Cancer | Advanced Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Metastatic Colorectal CarcinomaUnited States, Canada
-
Fusion Pharmaceuticals Inc.TerminatedCervical Cancer | Breast Cancer | Ovarian Cancer | Endometrial Cancer | Uveal Melanoma | Adrenocortical Carcinoma | Advanced Solid Tumours | HER2-negative Breast Cancer | Triple Negative Breast Cancer (TNBC) | Head and Neck Squamous Cell Carcinoma (HNSCC)United States, Australia, Canada
-
AstraZenecaRecruitingEGFR Mutation-positive NSCLCChina
-
3B Pharmaceuticals GmbHTerminatedGastric Cancer | Colorectal Cancer | Ewing Sarcoma | Squamous Cell Carcinoma of Head and Neck | Pancreatic Ductal Adenocarcinoma (PDAC) | NTSR1 Expressing Solid Tumours | Neuroendocrine Differentiated (NED) Prostate CancerUnited States, Australia
-
Fusion Pharmaceuticals Inc.Active, not recruitingMetastatic Castration-resistant Prostate CancerUnited States
-
Fusion Pharmaceuticals Inc.TerminatedBreast Cancer | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Lung Cancer | Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma | Liver Cancer | Bladder Carcinoma | Susceptible FGFR3 Genetic Alterations | FGFR3 | FGFR3 Overexpression | FGFR3 Receptor | FGFR3 Protein OverexpressionUnited States, Australia
-
Fusion Pharmaceuticals Inc.Active, not recruitingMetastatic Castration Resistant Prostate CancerUnited States
-
Suleyman Demirel UniversityCompletedFoot Deformities | Hallux Valgus | Pes Planus | Metatarsalgia | Feet Pes Planus (Flatfoot)Turkey
-
AstraZenecaNot yet recruitingMetastatic Prostate CancerItaly, Spain, United States, Germany, United Kingdom, Australia, South Korea
-
Paloma López RosNot yet recruitingFoot Deformities | Flatfoot